NTBL

Notable Labs, Ltd. Ordinary Shares

NTBL

Market cap $2.39M

Delisted

NTBL was delisted on the 22nd of October, 2024.

Back to rankings

About: Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.

Employees: 16

Healthcare Drug Manufacturers - General

Financial journalist opinion

Notable Labs to Present Data on September 4th at SOHO 2024

Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd.

Notable Labs to Present Data on September 4th at SOHO 2024

Notable Labs Announces CEO Transition

Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd.

Notable Labs Announces CEO Transition

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollment Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollment

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

Zacks Investment Research

Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now

Notable Labs (NTBL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024

FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced that Thomas Bock, M.D., Chief Executive Officer of Notable Labs, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024, taking place on May 13-14, 2024, in New York City.

Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024

Zacks Investment Research

Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock?

Notable Labs (NTBL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Notable Labs Reports 2023 Financial Results and Provides a Business Update

FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), reported financial results for the year ended December 31, 2023 and provided a business update.

Notable Labs Reports 2023 Financial Results and Provides a Business Update

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).

$Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024$

Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform

FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented data related to innovations in the use of cryopreserved samples in the PPMP assay at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 2548).

Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform

Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform

FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer therapies based on its Predictive Precision Medicine Platform (PPMP), today announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform

See News Rankings

Charts implemented using Lightweight Charts™